Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases.  The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday.  “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Dan Skovronsky, Lilly’s chief scientific and product officer, said in a statement.  Bloomberg News Health Reporter, Madison Muller, joins Paul Sweeney and Alexis Christoforous on "Bloomberg Intelligence" to analyze what's next for Eli Lilly after agreeing to buy three vaccine developers. (Source: Bloomberg)